[1] Brown AL, Kay GF. Bex1, a gene with increased expression in parthenogenetic embryos, is a member of a novel gene family on the mouse X chromosome. Hum Mol Genet, 1999, 8(4): 611-619.[2] Ryan SG, Chance PF, Zou CH, Spinner NB, Golden JA, Smietana S. Epilepsy and mental retardation limited to females: an X-linked dominant disorder with male sparing. Nat Genet, 1997, 17(1): 92-95.[3] Yang QS, Xia F, Gu SH, Yuan HL, Chen JZ, Yang QS, Ying K, Xie Y, Mao YM. Cloning and expression pattern of a spermatogenesis-related gene, BEX1, mapped to chromosome Xq22. Biochem Genet, 2002, 40(1-2): 1-12.[4] Behrens M, Margolis JW, Margolis FL. Identification of members of the Bex gene family as olfactory marker protein (OMP) binding partners. J Neuro-chem, 2003, 86(5): 1289-1296.[5] Vilar M, Murillo-Carretero M, Mira H, Magnusson K, Besset V, Ibáñez CF. Bex1, a novel interactor of the p75 neurotrophin receptor, links neurotrophin signaling to the cell cycle. EMBO J, 2006, 25(6): 1219-1230.[6] Foltz G, Ryu GY, Yoon JG, Nelson T, Fahey J, Frakes A, Lee H, Field L, Zander K, Sibenaller Z, Ryken TC, Vib-hakar R, Hood L, Madan A. Genome-wide analysis of epigenetic silencing identifies BEX1 and BEX2 as candi-date tumor suppressor genes in malignant glioma. Cancer Res, 2006, 66(13): 6665-6674.[7] Naderi A, Liu J, Bennett IC. BEX2 regulates mitochon-drial apoptosis and G1 cell cycle in breast cancer. Int J Cancer, 2010, 126(7): 1596-1610.[8] Kalpana GV, Marmon S, Wang W, Crabtree GR, Goff SP. Binding and stimulation of HIV-1 integrase by a human homolog of yeast transcription factor SNF5. Science, 1994, 266(5193): 2002-2006.[9] 吕湘, 刘德培, 梁植权. 染色质重塑复合物. 生命的化学, 2001, 21(2): 96-99.[10] Muchardt C, Sardet C, Bourachot B, Onufryk C, Yaniv M. A human protein with homology to Saccharomyces cerevisiae SNF5 interacts with the potential helicase hbrm. Nucleic Acids Res, 1995, 23(7): 1127-1132.[11] Kingston RE, Narlikar GJ. ATP-dependent remodeling and acetylation as regulators of chromatin fluidity. Genes Dev, 1999, 13(18): 2339-2352.[12] Cheng SW, Davies KP, Yung E, Beltran RJ, Yu J, Kalpana GV. c-MYC interacts with INI1/hSNF5 and requires the SWI/SNF complex for transactivation function. Nat Genet, 1999, 22(1): 102-105.[13] Zhang ZK, Davies KP, Allen J, Zhu L, Pestell RG, Zagzag D, Kalpana GV. Cell cycle arrest and repression of cyclin D1 transcription by INI1/hSNF5. Mol Cell Biol, 2002, 22(16): 5975-5988.[14] Rozenblatt-Rosen O, Rozovskaia T, Burakov D, Sedkov Y, Tillib S, Blechman J, Nakamura T, Croce CM, Mazo A, Canaani E. The C-terminal SET domains of ALL-1 and TRITHORAX interact with the INI1 and SNR1 proteins, components of the SWI/SNF complex. Proc Natl Acad Sci USA, 1998, 95(8): 4152-4157.[15] Wu DY, Krumm A, Schubach WH. Promoter-specific tar-geting of human SWI-SNF complex by Epstein-Barr virus nuclear protein 2. J Virol, 2000, 74(19): 8893-8903.[16] Lee D, Sohn H, Kalpana GV, Choe J. Interaction of E1 and hSNF5 proteins stimulates replication of human papillo-mavirus DNA. Nature, 1999, 399(6735): 487-491.[17] Adler HT, Chinery R, Wu DY, Kussick SJ, Payne JM, Fornace AJ Jr, Tkachuk DC. Leukemic HRX fusion pro-teins inhibit GADD34-induced apoptosis and associate with the GADD34 and hSNF5/INI1 proteins. Mol Cell Biol, 1999, 19(10): 7050-7060.[18] Morozov A, Yung E, Kalpana GV. Structure-function analysis of integrase interactor 1/hSNF5L1 reveals differential properties of two repeat motifs present in the highly conserved region. Proc Natl Acad Sci USA, 1998, 95(3): 1120-1125.[19] Versteege I, Sévenet N, Lange J, Rousseau-Merck MF, Ambros P, Handgretinger R, Aurias A, Delattre O. Trun-cating mutations of hSNF5/INI1 in aggressive paediatric cancer. Nature, 1998, 394(6689): 203-206.[20] Biegel JA, Fogelgren B, Zhou JY, James CD, Janss AJ, Allen JC, Zagzag D, Raffel C, Rorke LB. Mutations of the INI1 rhabdoid tumor suppressor gene in medulloblastomas and primitive neuroectodermal tumors of the central nervous system. Clin Cancer Res, 2000, 6(7): 2759-2763.[21] DeCristofaro MF, Betz BL, Wang WD, Weissman BE. Al-teration of hSNF5/INI1/BAF47 detected in rhabdoid cell lines and primary rhabdomyosarcomas but not Wilms' tu-mors. Oncogene, 1999, 18(52): 7559-7565.[22] Sévenet N, Lellouch-Tubiana A, Schofield D, Hoang-Xuan K, Gessler M, Birnbaum D, Jeanpierre C, Jouvet A, Delat-tre O. Spectrum of hSNF5IINI1 somatic mutations in human cancer and genotype-phenotype correlations. Hum Mol Genet, 1999, 8(13): 2359-2368.[23] Jagani Z, Mora-Blanco EL, Sansam CG, McKenna ES, Wilson B, Chen D, Klekota J, Tamayo P, Nguyen PT, Tol-storukov M, Park PJ, Cho YJ, Hsiao K, Buonamici S, Pomeroy SL, Mesirov JP, Ruffner H, Bouwmeester T, Lu-chansky SJ, Murtie J, Kelleher JF, Warmuth M, Sellers WR, Roberts CW, Dorsch M. Loss of the tumor suppressor Snf5 leads to aberrant activation of the Hedgehog-Gli pathway. Nat Med, 2010, 16(12): 1429-1433.[24] Guidi CJ, Mudhasani R, Hoover K, Koff A, Leav I, Imbalzano AN, Jones SN. Functional interaction of the reti-noblastoma and Ini1/Snf5 tumor suppressors in cell growth and pituitary tumorigenesis. Cancer Res, 2006, 66(16): 8076-8082.[25] Versteege I, Medjkane S, Rouillard D, Delattre O. A key role of the hSNF5/INI1 tumour suppressor in the control of the G1-S transition of the cell cycle. Oncogene, 2002, 21(42): 6403-6412. |